Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Co-DiagnosticsHAM:C970 63 5-Year Yield-on-Cost % is 0.00 as of Jul. 17, 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €4.73. The stock has 6 warning signs investors should review. Among 325 Medical Devices & Instruments companies, Co-Diagnostics ranks worse than 307692% on this metric.
Co-Diagnostics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Co-Diagnostics's 5-Year Yield-on-Cost % or its related term are showing as below:
HAM:C970's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.34 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Co-Diagnostics 5-Year Yield-on-Cost % Related Terms
HAM:C970 vs ALRTF, SINT, HSCS: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Co-Diagnostics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Co-Diagnostics is calculated as
Co-Diagnostics (HAM:C970) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Co-Diagnostics and its competitors. According to the industry distribution chart, Co-Diagnostics ranks #999999 out of 325 companies in the Medical Devices & Instruments industry.
Is Co-Diagnostics' 5-Year Yield-on-Cost % too high?
Co-Diagnostics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Co-Diagnostics ranks #999999 out of 325 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' 5-Year Yield-on-Cost % compare to ALRTF and SINT?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #999999 out of 325 companies for 5-Year Yield-on-Cost %. This places Co-Diagnostics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 325 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Co-Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Co-Diagnostics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €4.73, compared to a current price of €5.55 — trading 17.3% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 17.3% above its estimated GF Value™ of €4.73.
Key valuation signals for HAM:C970:
5-Year Yield-on-Cost %: 0.00
GF Value™: €4.73 vs. price of €5.55 (17.3% above fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score
Get the complete analysis for HAM:C970
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
